Replies to post #214848 on Biotech Values

[DewDiligence]

GNMK—(+34%)—is making decent money selling machines for COVID-19 testing; from 1Q20 PR:

https://finance.yahoo.com/news/genmark-diagnostics-provides-preliminary-financial-200310197.html

• Total revenue expected to be approximately $38.7 million, representing an increase of approximately 80% over the first quarter of 2019

o ePlex revenue expected to be approximately $34.3 million, an increase of approximately 119% compared to the first quarter of 2019

o Average annuity per analyzer of approximately $214,000, up 29% versus the first quarter of 2019

• COVID-19 positively impacted first quarter placements and revenue

o Approximately 80% of gross placements included interest in COVID-19 testing

o SARS-CoV-2 consumable revenue accounted for approximately 5% of total ePlex revenue

• Gross margin expected to be approximately 40%, compared to 27% in the first quarter of 2019